We are thrilled to announce our first in house developed product launch in the UK, which comes after a successful MHRA audit and receipt of our MIA and WDA in August this year. This launch showcases our regulatory, supply chain and operations agility whilst keeping compliance at the forefront of our priorities and is an important milestone in the journey of Zydus UK!

Our launch of Apixaban offers additional source of supply in the generic market, which will contribute to ensuring supply stability and enhance patient access to this medicine.

For more information, please visit the ‘Products’ page on our website or ‘Contact’ page to get in touch.